Faculty

Kiran Musunuru, MD, PhD, MPH, ML, MRA

Barry J. Gertz Professor for Translational Research

Department: Medicine

Graduate Group Affiliations

Cell and Molecular Biology

Contact information

Email:
kiranmusunuru@gmail.com

Education:
AB (Biochemical Sciences)
Harvard College, Cambridge, MA, 1997.
PhD (Biomedical Sciences)
The Rockefeller University, New York, NY, 2003.
MD (Medicine)
Weill-Cornell Medical College, New York, NY, 2004.
MPH (Epidemiology)
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2009.
ML (Law)
University of Pennsylvania Law School, Philadelphia, PA, 2019.
MRA (Regulatory Affairs)
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2024.

Permanent link

> Perelman School of Medicine > Faculty > Details

Selected Publications

IGVF Consortium: Deciphering the impact of genomic variation on function. Nature 633: 47-57, Sep 2024.

Riggan KA, Feys R, Kokayi A, Meagher KM, Michie M, Musunuru K, Ormond KE, Schelhaas AJ, Yap JQ, Isasi R, Allyse MA.: Grounded in reality: integrating community values and priorities of end users in human gene editing. Am J Bioeth 24: 43-45, Aug 2024.

Whittaker MN, Musunuru K.: An epigenetic editor to silence genes. Science 384: 1407-1408, Jun 2024.

Lv W, Babu A, Morley MP, Musunuru K, Guerraty MA.: Resource of gene expression data from a multiethnic population cohort of induced pluripotent stem cell-derived cardiomyocytes. Circ Genom Precis Med 17: e004218, Apr 2024.

Brooks DL, Whittaker MN, Said H, Dwivedi G, Qu P, Musunuru K, Ahrens-Nicklas RC, Alameh MG, Wang X.: A base editing strategy using mRNA-LNPs for in vivo correction of the most frequent phenylketonuria variant. HGG Adv 5: 100253, Jan 2024.

Brooks DL, Whittaker MN, Qu P, Musunuru K, Ahrens-Nicklas RC, Wang X.: Efficient in vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical need. Am J Hum Genet 110: 2003-2014, Dec 2023.

Musunuru K.: Playing the genetic lottery: an interview with Kiran Musunuru. Dis Model Mech 16: dmm050508, Oct 2023.

Whittaker MN, Testa LC, Quigley A, Jindal I, Cortez-Alvarado SV, Qu P, Yang Y, Alameh MG, Musunuru K, Wang X.: Epigenome editing durability varies widely across cardiovascular disease target genes. Arterioscler Thromb Vasc Biol 43: 2075-2077, Oct 2023.

Allyse MA, Meagher KM, Michie M, Isasi R, Ormond KE, Bonhomme N, Bombard Y, Howard H, Musunuru K, Riggan KA, Rubeck S.: Translational justice in human gene editing: bringing end user engagement and policy together. Am J Bioeth 23: 55-58, Jul 2023.

Testa LC, Musunuru K.: Base editing and prime editing: potential therapeutic options for rare and common diseases. BioDrugs 37: 453-462, Jul 2023.